Study protocol: Safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%) : A multicenter, open-label, single arm, phase II trial by L. Filippi et al.
STUDY PROTOCOL Open Access
Study protocol: safety and efficacy of
propranolol 0.2% eye drops in newborns
with a precocious stage of retinopathy of
prematurity (DROP-ROP-0.2%): a multicenter,
open-label, single arm, phase II trial
Luca Filippi1*, Giacomo Cavallaro2, Elettra Berti1, Letizia Padrini1, Gabriella Araimo2, Giulia Regiroli2,
Valentina Bozzetti3, Chiara De Angelis3, Paolo Tagliabue3, Barbara Tomasini4, Giuseppe Buonocore5,
Massimo Agosti6, Angela Bossi6, Gaetano Chirico7, Salvatore Aversa7, Roberta Pasqualetti8, Pina Fortunato8,
Silvia Osnaghi9, Barbara Cavallotti10, Maurizio Vanni11, Giulia Borsari11, Simone Donati12, Giuseppe Nascimbeni13,
Giancarlo la Marca14, Giulia Forni14, Silvano Milani15, Ivan Cortinovis15, Paola Bagnoli16, Massimo Dal Monte16,
Anna Maria Calvani17, Alessandra Pugi18, Eduardo Villamor19, Gianpaolo Donzelli1 and Fabio Mosca2
Abstract
Background: Retinopathy of prematurity (ROP) still represents one of the leading causes of visual impairment in
childhood. Systemic propranolol has proven to be effective in reducing ROP progression in preterm newborns,
although safety was not sufficiently guaranteed. On the contrary, topical treatment with propranolol eye micro-drops at
a concentration of 0.1% had an optimal safety profile in preterm newborns with ROP, but was not sufficiently effective
in reducing the disease progression if administered at an advanced stage (during stage 2). The aim of the present
protocol is to evaluate the safety and efficacy of propranolol 0.2% eye micro-drops in preterm newborns at a more
precocious stage of ROP (stage 1).
Methods: A multicenter, open-label, phase II, clinical trial, planned according to the Simon optimal two-stage design,
will be performed to analyze the safety and efficacy of propranolol 0.2% eye micro-drops in preterm newborns with
stage 1 ROP. Preterm newborns with a gestational age of 23–32 weeks, with a stage 1 ROP will receive propranolol
0.2% eye micro-drops treatment until retinal vascularization has been completed, but for no longer than 90 days.
Hemodynamic and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal
and liver functions, as well as electrocardiogram and echocardiogram, will be periodically performed to investigate
treatment safety. Additionally, propranolol plasma levels will be measured at the steady state, on the 10th day of
treatment. To assess the efficacy of topical treatment, the ROP progression from stage 1 ROP to stage 2 or 3 with plus
will be evaluated by serial ophthalmologic examinations.
Discussion: Propranolol eye micro-drops could represent an ideal strategy in counteracting ROP, because it is definitely
safer than oral administration, inexpensive and an easily affordable treatment. Establishing the optimal dosage and
treatment schedule is to date a crucial issue.
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Background
Background and rationale
Retinopathy of prematurity (ROP) is a potentially blinding
disease caused by pathologic angiogenesis that occurs in
the incompletely vascularized retina of preterm newborns.
Despite current therapeutic strategies, ROP still represents
a leading cause of potentially avoidable visual impairment
and blindness in childhood. More than 30,000 preterm
infants become blind or visually impaired from ROP each
year worldwide [1]. In the 1940s, the so-called “first ROP
epidemic” was related to the widespread use of unrestricted
oxygen supplementation; the second “ROP epidemic” oc-
curred in high-income countries in the 1970s and it was re-
lated to the increasing survival rate at lower gestational age
(GA) [2–4]. In the early 1990s, an emerging epidemic of
blindness due to ROP was also recorded in middle-income
countries [5]. Currently, Asia is the region presenting the
highest incidence of blindness due to ROP, followed by
Latin America, where some countries account for an inci-
dence of blindness/severe visual impairment related to
ROP that is 2.4 times higher than in highly industrialized
countries [1, 6, 7]. Therefore, the detection of a new inex-
pensive and easily affordable treatment strategy may be a
relevant issue of global interest. Prematurity and low birth
weight are the main factors associated with ROP, although
other factors (i.e. respiratory failure, fetal hemorrhage,
intra-ventricular hemorrhage, blood transfusions, hypergly-
cemia, sepsis, necrotizing enterocolitis) have been described
as contributing factors to ROP development [8, 9].
Physiologically, retinal blood vessels development begins
at the optic disc during the fourth month of gestation in
the hypoxic uterine environment and is completed at ap-
proximately 40 weeks of gestational age. The pathogenesis
of ROP has not yet been totally clarified, but the most vali-
dated hypothesis describes two different postnatal phases
[10]. During the first phase, the loss of the placenta and the
exposure to extrauterine relative hyperoxia are associated
with low levels of Vascular Endothelial Growth Factor
(VEGF) and Insulin-like Growth Factor 1 (IGF-1), resulting
in a cessation of retinal vascularization [11–14]. In fact,
oxygen induces retinal vasoconstriction, prevents retinal
vessel growth and therefore still represents one of the main
determinant of ROP development [15]. During the second
phase, the retinal maturation and the development of rela-
tive hypoxia stimulate the VEGF and IGF-1 expression,
causing a shift to a proliferative phase, which is character-
ized by an abnormal angiogenesis [16–18].
For a long time an oxygen saturation level lower than
90% has been suggested to reduce ROP risk. However, the
recent demonstration that a higher oxygen saturation
(91–95%) correlates with an improved survival represents
an actual dilemma because, unfortunately, it induces a
higher risk of ROP development [15]. Apart from oxygen
tension, which is the main factor promoting the expres-
sion of angiogenic growth factors in proliferative retinopa-
thies, other mechanisms are involved in the vascular
response to ischemia/hypoxia, including the activation of
inflammatory signaling pathways, oxidative stress and the
production of nitric oxide [19]. Genetic factors might also
affect the risk for ROP, even though no one has been iden-
tified thus far. The disease progresses more often in white
than black infants and in boys than girls [20, 21].
The role of the β-adrenergic system
Propranolol is a non-selective β-adrenoreceptor (β-AR)
antagonist. For many years, it has been largely used in
the pediatric population affected by cardiovascular dis-
eases (i.e. arterial hypertension, obstructive hypertrophic
cardiomyopathy, Fallot tetralogy and arrhythmia), hyper-
thyroidism (i.e. neonatal thyrotoxicosis), migraine and
portal hypertension with gastroesophageal varices at risk
of bleeding. Propranolol is also effective and sufficiently
safe in treating infantile hemangioma (IH) in childhood
[22–24] and the European Medicines Agency (EMA)
has recently authorized the use of propranolol for life-
threatening IH, at risk of ulceration or permanent de-
formation. The working mechanisms of propranolol in
reducing proliferative IH are not completely known and
include vasoconstriction, induction of epithelial cells
apoptosis and inhibition of angiogenesis [25–27]. The
growth of IH is enhanced by pro-angiogenic factors, in-
cluding VEGF and basic fibroblast growth factor (bFGF)
and propranolol inhibits the growth of IH by decreasing
the expression of pro-angiogenic factors and Hypoxia In-
ducible Factor 1 (HIF-1) induced by adrenergic receptors
[26–32]. Some pathogenic aspects of ROP are probably
common to IH, as suggested by the evidence that ROP
and IH often coexist in infants weighting <1250 g [33] and
that both diseases share the same histological feature. For
instance, endothelia of IH and of retinal neovasculature in
ROP express GLUT1 [34, 35], a factor significantly up-
regulated in hypoxic tissues and stimulated by HIF-1 [36].
Additionally, as for IH, the vascular proliferative phase
induced by hypoxia, which is the “second phase” in ROP
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pathogenesis, is promoted by VEGF. Considering that
both β1 and β2-ARs are expressed in the retina [37–40],
that hypoxia increases VEGF levels presumably through
overactivation of the β-adrenergic system as suggested
by norepinephrine accumulation in response to hypoxia
[41, 42], that β-AR blockade is effective in mouse models
of retinal neovascular diseases, our assumption was that
the use of β-AR blockers, such as propranolol, could be
useful for the treatment of ROP in infants. Indeed, sev-
eral studies using a mouse model of oxygen-induced
retinopathy (OIR) [43, 44] have analyzed the role of the
adrenergic system in the ROP pathogenesis and the effects
of β-AR antagonists and agonists on ROP development
[45–47]. These studies confirmed that retinal exposure to
hypoxia leads to an increase in catecholamine release,
which promotes the up-regulation of pro-angiogenic
factors and retinal angiogenesis by over-activating β-ARs
[46]. The β-AR blockade by systemic propranolol ad-
ministration decreases VEGF and IGF-1 levels, retinal
hemorrhage, retinal tufts and blood-retinal barrier
breakdown, improving the retinopathy score [45]. Similar
findings were observed using selective β2-AR blockade
[47] and after β2-AR desensitization following agonist ad-
ministration [46], confirming that β2-ARs play a central
role in the pathogenesis of ROP.
However, these findings obtained in C57BL/6 mice
seem to conflict with results reported in 129S6 mice, a
strain predisposed to develop a more aggressive neovas-
cularization [48] and characterized by an impressive up-
regulation of β3-ARs [49]. In this strain propranolol
does not seem to affect the retinal response to hypoxia
[49], but our hypothesis was that probably the different
genetic background of the mouse strain might contrib-
ute to the different retinal responses to hypoxia [50].
The hypothesis that the insensitivity to propranolol of
129S6 mice was due to the preponderance in this strain
of β3-ARs, that are minimally blocked by propranolol
[51], was confirmed by the discovery that this receptor is
involved in VEGF production in hypoxic retinas, through
the nitric oxide pathway [52]. The discovery of a proangio-
genic action of β3-ARs suggested to investigate a possible
role for this receptor also in cancer growth [53–55], a new
frontier of research currently for neonatologists.
Efficacy and safety of oral propranolol
The studies in the OIR model provided a considerable
amount of results which strongly indicate that β2-AR
blockade may play a significant action against hypoxia-
induced retinal neovascularization. This evidence prompted
an interest in exploring the possibility that the administra-
tion of propranolol may not only be used to treat IH but
also be of help in the treatment of ROP. A randomized
controlled trial [56] was performed to verify the efficacy
and safety of oral propranolol in preterm newborns
(GA < 32 weeks) with ROP stage 2 without plus in zone II
[57]. Oral propranolol significantly decreased ROP pro-
gression to both stage 3 and stage 3 with plus, and
none of treated newborns progressed to stage 4. The
number of newborns who underwent laser photocoagu-
lation or bevacizumab administration was significantly
lower in the treated group [56]. These data are consist-
ent with those reported by other authors [58–60]. Des-
pite propranolol being generally safe and well tolerated
in infancy, serious adverse events have been reported in
unstable preterm newborns, mainly in conjunction with
other conditions, such as sepsis, anesthesia or tracheal
stimulation [56]. In these patients receiving the lower dose
of 1 mg/kg/day, mean propranolol plasma concentration
was around 20 ng/mL. Considering that pharmacological
effects of β-blockers are usually related to the plasma con-
centrations, it appears prudent to avoid in future clinical
trials propranolol concentrations higher than 20 ng/mL,
that was considered a sort of safe cut-off value [56]. Al-
though propranolol is effective in counteracting ROP pro-
gression [56, 58–60], the incidence of adverse events
indicates that systemic administration is not sufficiently
safe in preterm newborns [56]. Recently, also prophylactic
propranolol administered on seventh day of life showed a
decreasing trend in the incidence of ROP, need for laser
therapy, and treatment with anti-VEGF [61].
Efficacy of propranolol eye drops in animal models
Since the oral administration of propranolol did not
guarantee adequate safety, further experiments investi-
gated the efficacy and safety of topical propranolol, in
the form of eye drops, in animal models. In 2013, Dal
Monte and co-workers demonstrated that 2% topical
propranolol administration provides the retina with a
drug concentration that are adequate to decrease pro-
angiogenic factors (VEGF and IGF-1), retinal angiogen-
esis and blood-retinal barrier breakdown in OIR mice
[62]. The efficacy and safety of topical propranolol were
also evaluated in a rabbit model [63]. Male New Zealand
white rabbits were treated with propranolol-based ocular
drops at 0.1% of concentration, applied every 6 h to both
eyes for 5 days. Retinal and plasma concentrations of
propranolol were measured and compared with those
registered after oral treatment. Despite retinal drug con-
centrations being similar to those reported after oral
treatment, plasma propranolol levels were significantly
lower after topical administration. Additionally, Draize
test (a classical acute toxicity test) and cornea’s histo-
logical analysis showed no significant differences be-
tween control and treated eyes, confirming that local
tolerability of ocular propranolol drops was optimal. All
these findings suggested that topical propranolol formu-
lation might be equally effective as systemic administra-
tion but have a better safety profile.
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Safety and efficacy of propranolol 0.1% eye micro-drops in
newborns
Recently an open-label, trial was performed to evaluate
the safety and efficacy of propranolol 0.1% eye micro-
drops in preterm newborns with stage 2 ROP without plus
[64]. The study was planned according to the Simon opti-
mal two-stage design for phase II clinical trials and it was
discontinued before starting the second stage since the
number of failures was above the set threshold. Even
though the objective to move to the second stage was not
reached, the percentage of ROP progression (around 26%)
was substantially similar to that obtained after oral pro-
pranolol administration. Nevertheless, no adverse effects
were observed and propranolol plasma levels were signifi-
cantly lower than those measured after oral administration
(consistently below the cut-off value of 20 ng/mL). There-
fore, treatment with propranolol 0.1% eye micro-drops
seems to be safe and well tolerated in preterm newborns,
but not sufficiently effective in reducing ROP progression.
Further research is then required to identify the optimal
dose and schedule of topical propranolol therapy for ROP.
Research hypothesis
The present open-label trial is planned to evaluate safety
and efficacy of propranolol 0.2% eye micro-drops in pre-
term newborns with stage 1 ROP without plus.
Study objectives
Primary objective
To evaluate the safety and efficacy of propranolol 0.2%
eye micro-drops in preventing ROP progression from
Stage 1 without plus to Stage 2 with plus or 3 with plus
and therefore in reducing the rate of laser treatment and
rescue treatment with bevacizumab.
Secondary objective
To analyze the efficacy of propranolol 0.2% eye micro-
drops in preventing ROP progression from Stage 1 without
plus to more severe Stage ROP.
Trial design
The present study is a multicenter, open-label, single
arm phase II trial planned as a Simon optimal two-stage
design [65], under the hypothesis that the treatment de-
creases the incidence of ROP progression to stage 3 with
plus (estimated from historical data to be at least 19%)
by 50% or more.
Methods: Participants, interventions, outcomes
Study setting
Preterm newborns delivered at GA ranging from 23 to
32 weeks and admitted to the neonatal intensive care units
(NICU) contributing to the study (1. Meyer University
Children’s Hospital in Florence; 2. Institute of Pediatrics
and Neonatology, Fondazione IRCCS Ospedale Maggiore
Policlinico, Mangiagalli e Regina Elena, Università di Mi-
lano; 3. San Gerardo Hospital in Monza; 4. University
Hospital Policlinico Santa Maria alle Scotte, Siena; 5. Uni-
versity Hospital in Varese; 6. Children’s Hospital Spedali
Civili in Brescia) were considered for enrolment.
Inclusion criteria
The following inclusion criteria were considered:
1. Preterm newborns (GA 23–32 weeks) with birth
weight < 1500 g diagnosed with stage 1 ROP in zone
II or III, without plus;
2. A signed informed consent from parents.
Exclusion criteria
1. Newborns with heart failure, congenital
cardiovascular anomalies except for persistent
ductus arteriosus, patent foramen ovale and small
ventricular septal defects, recurrent bradycardia
(heart rate < 90 beat per minute), second or third
degree atrio-ventricular block, intractable
hypotension, renal failure, current cerebral
hemorrhage, other diseases which contraindicate the
use of β-AR blockers.
2. Newborns with ROP at a more advanced stage than
stage 1.
3. Newborns with aggressive posterior ROP (AP-ROP).
Intervention
All enrolled newborns will receive propranolol as oph-
thalmic solution (0.2%). Three micro-drops of 6 μL pro-
pranolol solution (= 6 μg propranolol/μ-drops) will be
topically applied four times daily (every 6 h) in each eye
with a calibrated pipette. After propranolol administra-
tion, the nasolacrimal duct will be carefully compressed
for 1 min in order to decrease the percentage of drug
absorbed by the conjunctival and nasal vessels. The
treatment will be started as soon as the diagnosis of
stage 1 ROP without plus is confirmed and will be
continued until the complete development of retinal
vascularization, but for no longer than 90 days. However,
ophthalmologic exams will also be performed after this
period to exclude possible rebound phenomenon. In these
cases, propranolol eye micro-drops treatment will be re-
sumed until retinal vascularization is completed.
The ophthalmologic approach for newborns enrolled
in the study will be in accordance with the guidelines
adopted by the ETROP Cooperative Group and the
AAP/AAO/AAPOS guidelines [3, 66, 67]. The RetCam
Imaging System will be systematically used by ophthal-
mologists to evaluate ROP evolution.
Filippi et al. BMC Pediatrics  (2017) 17:165 Page 4 of 10
Eye drops will be prepared sterilely by diluting pro-
pranolol hydrochloride powder (ACEF, Fiorenzuola
d’Arda, Piacenza, Italy), in sterile water for injection at a
concentration of 2%. Then, the propranolol 0.2% solu-
tion will be obtained in a horizontal laminar flow hood
adding 9 ml of saline solution to 1 ml of propranolol 2%
preparation.
Newborns with ROP who progressed to stage 2 plus
or stage 3 plus will be treated with laser photocoagula-
tion or intravitreal anti-VEGF (bevacizumab) administra-
tion. The ophthalmologists will choose the treatment
they will consider most appropriate.
Modification
Stop criteria and dose changes
Considering that unstable newborns (i.e. after anesthesia
induction) have shown a high risk of adverse events
(hypotension and bradycardia) due to propranolol ad-
ministration, whenever surgery and/or anesthesia are
indicated, the discontinuation of the propranolol eye
micro-drops treatment is recommended at least 24 h
before.
Newborns in whom propranolol administration will be
temporarily suspended for more than two doses, with
the exception of a temporary suspension before surgery
will be excluded from the study.
In the case of a severe adverse event (bradycardia,
bronchospasm, severe hypotension or severe local signs)
due to propranolol eye micro-drops therapy, the treat-
ment will be promptly stopped and the newborn will be
excluded from the study. The concentration of propran-
olol will be measured on dried blood spots to verify the
relationship between the adverse event that occurred
and the plasmatic levels of propranolol. Moreover, after
the first adverse event, the study could be restarted re-
ducing the propranolol eye drops dosage to two micro-
drops of 6 μL 0.2% propranolol solution administered
four times daily in each eye. An additional enrolment
phase will be opened and will be based on a new study
population not including newborns previously treated.
Similarly, the study could be restarted increasing the
concentration of propranolol eye drops solution up to
0.3% in case of treatment failure in terms of efficacy dur-
ing the first stage of the study, if plasma propranolol
concentrations are below the cut off of 20 ng/ml.
The outcomes of infants who develop adverse effects
to propranolol will be reported to Pharmacovigilance
Center and then published.
Methods: Data collection, management, analysis
Data collection methods
All data will be registered in specific case report form
including neonatal demographic data, prenatal and
perinatal history and morbidity profiles of both mother
and newborn. Hemodynamic parameters, diuresis and
respiratory parameters will be continuously monitored
during the first 3 weeks of treatment. Biochemical pa-
rameters, such as a complete blood count, serum elec-
trolytes levels, renal and liver function tests will be
measured before starting treatment (T0) and once a
week for the first 3 weeks of treatment (T7, T14, and
T21). Electrocardiogram and echocardiogram will be
performed before starting treatment and once a week
for 3 weeks of treatment. Any drugs that are concomi-
tantly administered and procedures performed will be
recorded.
To investigate the safety of propranolol 0.2% eye
micro-drops treatment, the concentration of propranolol
will be measured on dried blood spots using the liquid-
chromatography tandem-mass spectrometry test [68, 69]
at the steady state on the 10th day of treatment, before
administering therapy (T0), after 2 (T2), 4 (T4) and 6 h
(T6). Additionally, parents will be asked to consent to us
taking and storing 0.3 ml of plasma.
The stage of ROP disease should be established by
complete ophthalmological evaluations, planned ac-
cording to ROP Guidelines [3, 66, 67], also considering
the progression and the severity of ROP. The ophthal-
mologic exam should verify the absence of local adverse
events due to the propranolol eye micro-drops treatment,
as well as analyze corneal and vitreous transparencies, lens
opacity, and regression of vessels in the tunica vasculosa
lentis. The ROP progression will be monitored by indirect
ophthalmoscopy using a 20D and 28D lens. The RetCam
Imaging System will be systematically used by ophthal-
mologists to evaluate ROP evolution.
The timeline of the study is reported in Additional file 1.
All the adverse effects will be notified to the qualified
responsible of pharmacovigilance, using the specified re-
port form.
Statistical methods
Preliminary analysis
To plan the present multicenter, open-label, single arm,
phase II trial, a preliminary analysis was performed to
evaluate historical ROP incidence in the 6 NICUs in-
volved in the study.
This analysis included all preterm newborns admitted
to the NICUs contributing to the study (Florence, Milan,
Monza, Siena, Varese, Brescia) and diagnosed with any
stages of ROP from 2011 to 2015. During the 5 years
preceding the present study, 248 patients out of 2165
very low birth weight newborns (11.5%) were diagnosed
with ROP. Demographic and obstetric characteristics of
this historical cohort are reported in Table 1. However,
only 237 of these newborns (95.6%) shared the same en-
rollment criteria of this planned trial. In fact, 3 newborns
were suffering from AP-ROP and 8 newborns showed a
Filippi et al. BMC Pediatrics  (2017) 17:165 Page 5 of 10
ROP ≥ stage 2 at first examination. Therefore, in Table 1
we also show the demographic and obstetric characteris-
tics of these 237 newborns who showed ROP stage 1 at
first examination.
A total of 63 newborns out of 248 diagnosed with any
stage of ROP (25.4%) showed a stage 2 or 3 with plus
and received a treatment (Table 2). The same analysis
was repeated excluding the three newborns suffering
from AP-ROP, and the eight newborns who showed a
ROP stage ≥2 at first examination. Regarding the 237
newborns that showed ROP stage 1 at first examination,
58 (24.5%) progressed from stage 1 to stage 2 or 3 with
plus. Overall, 45 newborns underwent laser photocoagula-
tion, while 27 newborns were treated with bevacizumab
administration (14 newborns, in fact, received both treat-
ments). Four patients progressed to stage 4 ROP and were
treated with vitrectomy (one also with cryotherapy). Fi-
nally, one newborn progressed to stage 5 ROP. These data
were used to plan the current prospective study.
Endpoint
For the present multicenter, open-label, single arm, phase
II trial, the following endpoint will be evaluated:
Primary endpoint
-Number of infants who progress from ROP Stage 1 in
zone II or III, without plus to Stage 2 with plus or
Stage 3 with plus.
-Analysis of propranolol plasma concentration at the
steady state (on the tenth day of treatment).
Secondary endpoint
-Number of infants who progress to Stage 2 without
plus ROP.
-Number of infants who progress to Stage 3 without
plus ROP.
-Number of infants who progress to Stage 4 or 5 ROP
with total or partial retinal detachment.
-Number of infants who need vitrectomy.
-Number of adverse events due to propranolol eye
drops treatment.
Experimental plan
The study was planned as a Simon optimal two-stage de-
sign [65] (Fig. 1), under the hypothesis that propranolol
Table 1 Demographic and obstetric characteristics of historical cohort, co-morbidities and co-interventions
Demographic and obstetric characteristics Any stage ROP Stage 1 ROP at first visit
Newborns, n (%) 248 237 (95.6)
Gestational age, weeks, mean ± SD 26.6 ± 2.0 26.7 ± 2.0
Birth weight, g, mean ± SD 838 ± 233 843 ± 235
Male, n (%) 129 (52.0) 126 (53.2)
Caesarean delivery, n (%) 170 (68.5) 162 (68.3)
Stained amniotic fluid, n (%) 18 (7.3) 16 (6.7)
Apgar Score, 1 min, mean ± SD 4.6 ± 2.3 4.6 ± 2.3
Apgar Score, 5 min, mean ± SD 7.4 ± 1.7 7.4 ± 1.7
Post menstrual age at diagnosis, weeks, mean ± SD 34.1 ± 2.2 34.2 ± 2.3
Co-morbidities and co-intervention
Respiratory distress syndrome, n (%) 239 (96.4) 228 (96.2)
Surfactant treatment, n (%) 208 (83.9) 198 (83.5)
Duration of oxygen exposure (days), median (range) 49.4 (0–291) 46.7 (0–291)
Bronchopulmonary dysplasia a, n (%) 170 (68.5) 160 (67.5)
Candida sepsis, n (%) 12 (4.8) 12 (5.1)
Other sepsis, n (%) 143 (57.7) 132 (55.7)
Number of red blood cell transfusions, median (range) 5 (0–19) 5 (0–19)
Intraventricular hemorrhage, grade 3–4, n (%) 40 (16.1) 38 (16.0)
Post-hemorrhagic hydrocephalus, n (%) 17 (6.8) 15 (6.3)
Cholestasis, n (%) 66 (26.6) 60 (25.3)
Necrotizing enterocolitis, n (%) 32 (12.9) 31 (13.1)
Gastrointestinal perforation, n (%) 26 (10.5) 25 (10.5)
Surgical closure of patent ductus arteriosus, n (%) 56 (22.6) 52 (21.9)
Survival, n (%) 245 (98.8) 234 (98.7)
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0.2% eye micro-drops treatment decreases the incidence
of ROP progression to stage 2 or 3 with plus by at least
50%. From a first analysis of the historical cohort of neo-
nates the incidence was found to be 19%. A second and
deeper analysis showed that the incidence was likely some-
what higher (24.5%) (Table 2). The study size adopted is
based on the first and more conservative estimate. There-
fore, considering an alpha error of 0.05 and a power of
80%, the treatment should be considered failed if:
-at least 6 cases of failure (a progression of ROP to
stage 2 with plus or 3 with plus) is observed in the first
37 newborns enrolled;
-at least 13 out of 96 newborns enrolled show a
treatment failure (a progression of ROP to stage 2 with
plus or 3 with plus).
At the end of the study, if the overall cases of failure
are less than 13 out of 96 newborns, the treatment with
propranolol 0.2% eye drops will be considered effective
in decreasing the rate of ROP progression to stage 2 or
3 with plus.
Additionally, considering the serious adverse effects
observed in newborns receiving oral propranolol with
plasma concentrations around 20 ng/mL, this value is
currently considered a sort of safe cut-off value [55].
For this reason, if the mean propranolol plasma con-
centration will be less than 20 ng/ml, as expected, the
treatment with propranolol eye drops should be consid-
ered safe, being unable to cause high plasma levels of
propranolol.
The 96 preterm newborns will be enrolled approxi-
mately in 2–3 years. The enrokllment will be competitive:
the individual centers participating in the trial will not
have a predetermined number of patients to recruit, but
they will compete with each other to recruit all expected
patients. The trial will be completed when the last new-
born enrolled has completed the treatment schedule or
achieved final retinal vascularization.
Table 2 Ophthalmologic outcome of historical cohort
ROP progression Any stage ROP Stage 1 ROP
at first visit
Newborns, n (%) 248 237 (95.6)
Aggressive Posterior ROP, n (%) 3 (1.2)
Stage ≥2 at first examination, n (%) 8 (3.2)
Stage 1 ROP at first examination, n (%) 237 (95.6)
Stage 2, n (%) 172 (69.3) 165 (69.6)
Stage 3, n (%) 72 (29.0) 68 (28.7)
Stage 2 or 3 ROP with plus, n (%) 63 (25.4) 58 (24.5)
Stage 4 ROP, n (%) 4 (1.6) 4 (1.7)
Stage 5 ROP, n (%) 1 (0.4) 1 (0.4)
Treatment with laser photocoagulation,
n (%)
47 (18.9) 45 (19.0)
Treatment with bevacizumab, n (%) 30 (12.1) 27 (11.4)
Vitrectomy, n (%) 4 (1.6) 4 (1.7)
Cryotherapy, n (%) 1 (0.4) 1 (0.4)
Fig. 1 Simon optimal two-stage design for phase II clinical trials
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Ethics
Research ethics approval
The phase II study entitled “Study protocol: Safety and
efficacy of propranolol 0.2% eye drops in newborns with
retinopathy of prematurity: a phase II study (DROP-
ROP-0.2%)” has been ethically approved by the Ethics
Committees of centers involved in the trial and by the
Italian Medicines Agency (AIFA/RSC/P/59172). Approval
was obstained from Comitato Etico Pediatrico Regione To-
scana (for Meyer University Children’s Hospital of Florence,
and for University Hospital Policlinico Santa Maria alle
Scotte, Siena), from Comitato Etico Milano Area B (Insti-
tute of Pediatrics and Neonatology, Fondazione IRCCS
Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena,
Università di Milano), from Comitato Etico della Provincia
Monza Brianza (San Gerardo Hospital in Monza), from
Comitato Etico Provinciale di Varese (University Hospital
in Varese) and from Comitato Etico della Provincia di
Brescia (Children’s Hospital Spedali Civili in Brescia).
Whenever a newborn meets the inclusion criteria, parents
should be informed on the aim, the procedures and the
risks of the study. Then, signed parental informed consent
is to be obtained from a physician responsible of the study
prior to the enrolment.
Discussion
The aim of the present study is to evaluate the therapeutic
role of propranolol 0.2% eye micro-drops in newborns
with a precocious stage of ROP. Treatment with oral pro-
pranolol is effective in preventing ROP progression in pre-
term newborns, but appears unsafe. Furthermore, data
from a previous trial suggested that propranolol 0.1% eye
micro-drops had an optimal safety and tolerability profile
in preterm newborns, although efficacy in reducing ROP
progression was not sufficient. The optimal dosage and
concentration of propranolol eye drops to use in preterm
newborns are still uncertain. However, considering the
optimal safety profile of propranolol 0.1% eye micro-
drops, it is likely that this dosage could be increased
without compromising safety. Similarly, the excellent
local tolerability also suggests that the concentration of
propranolol solution could be increased without the
risk of local adverse reactions. According to these con-
siderations, the present protocol study plans to increase
both dosage and concentration of propranolol eye
drops in order to improve the efficacy profile. Add-
itionally, the optimal time to start propranolol treat-
ment has not yet been clarified. In the previous study
with 0.1% eye micro-drops, the treatment was started
at an advanced stage of ROP (stage 2 without plus), a stage
that is quite close to the threshold of ophthalmological
treatment. Therefore, we assumed that starting therapy
at an earlier stage of ROP (stage 1) could represent an
additional advantage.
Finding the optimal dosage and schedule of propranolol
eye micro-drops treatment could represent a crucial
turning point in ROP therapy. In fact, propranolol eye
drops is apparently a safe, inexpensive and easily afford-
able treatment. Considering also the high prevalence of
ROP registered in middle income countries, these advan-
tages become even more relevant.
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Additional file 1: BMC Pediatrics Appendix 1. Study timeline. Appendix 1
reports the timeline of the study. (DOC 50 kb)
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